Cargando…

Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant

BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as prophylaxis against Pneumocystis pneumonia (PCP) in renal transplant recipients. The optimal duration of prophylaxis is unknown. Longer duration of prophylaxis may increase the risk of adverse effects. The aim of this retrospectiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Chapman, Fiona A., Dickerson, Jonathan E., Daly, Conal, Clancy, Marc, Geddes, Colin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918803/
https://www.ncbi.nlm.nih.gov/pubmed/31806862
http://dx.doi.org/10.12659/AOT.918195
_version_ 1783480663596335104
author Chapman, Fiona A.
Dickerson, Jonathan E.
Daly, Conal
Clancy, Marc
Geddes, Colin
author_facet Chapman, Fiona A.
Dickerson, Jonathan E.
Daly, Conal
Clancy, Marc
Geddes, Colin
author_sort Chapman, Fiona A.
collection PubMed
description BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as prophylaxis against Pneumocystis pneumonia (PCP) in renal transplant recipients. The optimal duration of prophylaxis is unknown. Longer duration of prophylaxis may increase the risk of adverse effects. The aim of this retrospective observational cohort study was to assess the impact of increasing duration of TMP-SMX prophylaxis from 3 to 6 months after transplant on drug-resistant urinary tract infection (UTI), hyperkalemia, peripheral blood cytopenias, and incidence of PCP. MATERIAL/METHODS: Patients transplanted over a 4.5-year period before and after a change in protocol from 3- to 6-months TMP-SMX prophylaxis in our unit were grouped according to planned duration of prophylaxis, and results were analyzed on an intention-to-treat basis. Baseline characteristics, laboratory values, and all urine microbiology results in the 6 months after transplant were analyzed. RESULTS: The overall UTI incidence rate was higher in the 3-month (3-m) treatment group than the 6-month (6-m) treatment group (0.52 vs. 0.33 UTI per 100 patient days; rate ratio 1.56 [95% CI 1.27–1.95]). However, this was not attributable to TMP-SMX: the incidences were significantly different in months 0–3 but not months 4–6. Twenty-eight multi-resistant UTIs occurred in the 3-m group, but there were none in the 6-m group (p=0.004). There were no significant differences in renal function, serum potassium, or cytopenias during the first 6 months. There were 15 cases of PCP in the 3-m group, 3 cases in the 6-m group, and no cases during prophylaxis. CONCLUSIONS: Extending the duration of TMP-SMX prophylaxis was not associated with change in frequency of UTIs or multi-drug-resistant UTIs, nor was it associated with increased adverse events. TMP-SMX is an effective PCP prophylaxis, and these data support recommendations to extend the duration of prophylaxis after transplant.
format Online
Article
Text
id pubmed-6918803
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-69188032019-12-26 Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant Chapman, Fiona A. Dickerson, Jonathan E. Daly, Conal Clancy, Marc Geddes, Colin Ann Transplant Original Paper BACKGROUND: Trimethoprim-sulfamethoxazole (TMP-SMX) is recommended as prophylaxis against Pneumocystis pneumonia (PCP) in renal transplant recipients. The optimal duration of prophylaxis is unknown. Longer duration of prophylaxis may increase the risk of adverse effects. The aim of this retrospective observational cohort study was to assess the impact of increasing duration of TMP-SMX prophylaxis from 3 to 6 months after transplant on drug-resistant urinary tract infection (UTI), hyperkalemia, peripheral blood cytopenias, and incidence of PCP. MATERIAL/METHODS: Patients transplanted over a 4.5-year period before and after a change in protocol from 3- to 6-months TMP-SMX prophylaxis in our unit were grouped according to planned duration of prophylaxis, and results were analyzed on an intention-to-treat basis. Baseline characteristics, laboratory values, and all urine microbiology results in the 6 months after transplant were analyzed. RESULTS: The overall UTI incidence rate was higher in the 3-month (3-m) treatment group than the 6-month (6-m) treatment group (0.52 vs. 0.33 UTI per 100 patient days; rate ratio 1.56 [95% CI 1.27–1.95]). However, this was not attributable to TMP-SMX: the incidences were significantly different in months 0–3 but not months 4–6. Twenty-eight multi-resistant UTIs occurred in the 3-m group, but there were none in the 6-m group (p=0.004). There were no significant differences in renal function, serum potassium, or cytopenias during the first 6 months. There were 15 cases of PCP in the 3-m group, 3 cases in the 6-m group, and no cases during prophylaxis. CONCLUSIONS: Extending the duration of TMP-SMX prophylaxis was not associated with change in frequency of UTIs or multi-drug-resistant UTIs, nor was it associated with increased adverse events. TMP-SMX is an effective PCP prophylaxis, and these data support recommendations to extend the duration of prophylaxis after transplant. International Scientific Literature, Inc. 2019-12-06 /pmc/articles/PMC6918803/ /pubmed/31806862 http://dx.doi.org/10.12659/AOT.918195 Text en © Ann Transplant, 2019 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Original Paper
Chapman, Fiona A.
Dickerson, Jonathan E.
Daly, Conal
Clancy, Marc
Geddes, Colin
Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
title Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
title_full Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
title_fullStr Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
title_full_unstemmed Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
title_short Impact of Increased Duration of Trimethoprim-Sulfamethoxazole Prophylaxis for Pneumocystis Pneumonia After Renal Transplant
title_sort impact of increased duration of trimethoprim-sulfamethoxazole prophylaxis for pneumocystis pneumonia after renal transplant
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918803/
https://www.ncbi.nlm.nih.gov/pubmed/31806862
http://dx.doi.org/10.12659/AOT.918195
work_keys_str_mv AT chapmanfionaa impactofincreaseddurationoftrimethoprimsulfamethoxazoleprophylaxisforpneumocystispneumoniaafterrenaltransplant
AT dickersonjonathane impactofincreaseddurationoftrimethoprimsulfamethoxazoleprophylaxisforpneumocystispneumoniaafterrenaltransplant
AT dalyconal impactofincreaseddurationoftrimethoprimsulfamethoxazoleprophylaxisforpneumocystispneumoniaafterrenaltransplant
AT clancymarc impactofincreaseddurationoftrimethoprimsulfamethoxazoleprophylaxisforpneumocystispneumoniaafterrenaltransplant
AT geddescolin impactofincreaseddurationoftrimethoprimsulfamethoxazoleprophylaxisforpneumocystispneumoniaafterrenaltransplant